Daniel J. Trepanier

Dr. Trepanier first began working on cyclophilin in 1996, and has 22 years’ field experience in the pharmaceutical industry with strong emphasis on cyclosporine and novel cyclophilin inhibitors. He has direct hands-on expertise in drug discovery, analytical and bioanalytical method development and analysis, preclinical pharmacokinetic, toxicological and toxicokinetic studies, formulation development, drug manufacturing, preparation of preclinical regulatory submissions, and interfacing with contract research organizations and patent attorneys. Dr. Trepanier is the developer of Aurinia Pharmaceuticals’ voclosporin formulation which has been tested in more than 2,600 patients and is nearing commercialization. He was Director of Drug Development at Ciclofilin Pharmaceuticals and retained this position following a merger with Hepion Pharmaceuticals in 2016.

Dr. Trepanier holds a BSc degree in chemistry and an MSc degree in biochemistry (Concordia University, Quebec), and a PhD in clinical chemistry (University of Windsor, Ontario). He completed a postdoctoral fellowship (University of Alberta) specializing in analytical chemistry. Dr. Trepanier is the author or co-author of numerous scientific papers, abstracts and patents.